vobramitamab duocarmazine

Vobramitamab duocarmazine is an investigational antibody-drug conjugate (ADC) developed by MacroGenics. It consists of a humanized IgG1/kappa monoclonal antibody targeting B7-H3 (CD276), a member of the B7 family that is highly expressed in many solid tumors and associated with poor prognosis. The ADC is conjugated to a duocarmycin-based cytotoxic payload via a cleavable linker, enabling targeted delivery and DNA alkylation within tumor cells. The drug-to-antibody ratio is approximately 2.7. Vobramitamab duocarmazine has demonstrated robust preclinical activity against adult and pediatric cancer models and has shown promising efficacy and manageable safety in phase 1/2 clinical trials for metastatic castration-resistant prostate cancer (mCRPC). It is also being explored for other solid tumors including small cell lung cancer and neuroblastoma[1][3][4][5][6][10].

Brand names

vobra duo

Other names

anti-B7-H3 antibody-drug conjugateanti-B-7-H3 antibody-drug conjugateanti-B 7-H3 antibody-drug conjugateanti-b7h3 antibody-drug conjugate mgc018anti-b-7h3 antibody-drug conjugate mgc018anti-b 7h3 antibody-drug conjugate mgc018